Dx & Vx Co Ltd
KOSDAQ:180400
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Dx & Vx Co Ltd
Other Equity
Dx & Vx Co Ltd
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Dx & Vx Co Ltd
KOSDAQ:180400
|
Other Equity
₩385.6m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Other Equity
₩533.6B
|
CAGR 3-Years
57%
|
CAGR 5-Years
62%
|
CAGR 10-Years
39%
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Other Equity
₩12B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Other Equity
₩51.3B
|
CAGR 3-Years
129%
|
CAGR 5-Years
89%
|
CAGR 10-Years
43%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Other Equity
₩20.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Other Equity
₩42.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Dx & Vx Co Ltd
Glance View
Dx & Vx Co., Ltd. engages in the development of molecular diagnostic products. The company is headquartered in Seoul, Seoul. The company went IPO on 2014-12-15. The Molecular Diagnosis Business segment is engaged in the manufacture and sale of deoxyribonucleic acid (DNA) chips, polymerase chain reaction (PCR) chips and other products. manufacture and sale of diagnostic reagents used for molecular diagnosis, and various enzymes and experimental reagents used for biological research.
See Also
What is Dx & Vx Co Ltd's Other Equity?
Other Equity
385.6m
KRW
Based on the financial report for Sep 30, 2025, Dx & Vx Co Ltd's Other Equity amounts to 385.6m KRW.
What is Dx & Vx Co Ltd's Other Equity growth rate?
Other Equity CAGR 5Y
12%
Over the last year, the Other Equity growth was 219%. The average annual Other Equity growth rates for Dx & Vx Co Ltd have been -21% over the past three years , 12% over the past five years .
